ArticleJournal of cardiovascular translational research2025
The Clinical Significance of miR-139-5p in Acute Coronary Syndrome and its Potential Effect on the Progression of Acute Coronary Syndrome.
Article in Journal of cardiovascular translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- MicroRNA Signatures in Cardiometabolic Disorders as a Next-Generation Diagnostic Approach: Current Insight.International journal of molecular sciences · 2025Review
- Upregulation of Serum miRNA-3615 Serves as a Biomarker to Predict Disease Onset and Prognosis in Acute Coronary Syndrome Patients.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To investigate the role of miR-139-5p in acute coronary syndrome (ACS), serum miR-139-5p levels were measured via quantitative real-time polymerase chain reaction (qRT-PCR) in 117 ACS patients, 91 stable angina (SAP) patients, 89 healthy controls. Its associations with ACS severity, major adverse cardiovascular events (MACE) were evaluated using statistical tests, Kaplan-Meier survival, COX regression analysis. Effect of miR-139-5p on cell function and inflammation in oxidized low-density lipoprotein (ox-LDL) -induced human coronary artery smooth muscle cells (HCASMCs) was evaluated in vitro. Upregulated miR-134-5p in ACS distinguished ACS from SAP/health individuals, correlating with increased cardiac troponin I (cTnI), Gensini score, MACE risk. COX regression identified miR-139-5p as independent ACS prognostic factors. In vitro, miR-139-5p downregulation suppressed ox-LDL-induced HCASMC proliferation, migration, and inflammation. Upregulated miR-139-5p expression showed a diagnostic and prognostic value on ACS and was correlated with ACS severity. Downregulated miR-139-5p expression exhibited a suppressive effect on ACS progression.
Indexed as
Identifiers
40439867What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.